BRCA1, BRCA2 and CHEK2 c.1100 delC mutations in patients with double primaries of the breasts and/or ovaries

Journal of Medical Genetics

Volumn 47, Issue 8, 2010, Pages 561-566

  Evans, D Gareth ^a,b   Ahmed, Munaza ^a   Bayliss, Stuart ^a   Howard, Emma ^a   Lalloo, Fiona ^a   Wallace, Andrew ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

^b WYTHENSHAWE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CHECKPOINT KINASE 2;

ADULT; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER RISK; CONTROLLED STUDY; FAMILY HISTORY; FEMALE; GENE MUTATION; GENETIC ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; RELATIVE;

BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; FAMILY; FEMALE; HUMANS; MIDDLE AGED; MODELS, GENETIC; MUTATION; NEOPLASMS, MULTIPLE PRIMARY; OVARIAN NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; SENSITIVITY AND SPECIFICITY;

EID: 77956097177     PISSN: 00222593     EISSN: 14686244     Source Type: Journal    
DOI: 10.1136/jmg.2009.075770     Document Type: Article

References (22)

1. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994;266:66-71.
2. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C, Micklem G. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995;378:789-92.
3. Schorge JO, Mahoney NM, Miller DS, Coleman RL, Muller CY, Euhus DM. Tomlinson GE.Germline BRCA1-2 mutations in non-Ashkenazi families with double primary breast and ovarian cancer. Gynecol Oncol 2001;83:383-7.
4. Fishman A, Dekel E, Chetrit A, Lerner-Geva L, Bar-Am A, Beck D, Beller U, Ben-Baruch G, Piura B, Friedman E, Struewing JP, Modan B. Patients with double primary tumors in the breast and ovary- clinical characteristics and BRCA1-2 mutations status. Gynecol Oncol 2000;79:74-8.
5. Cvelbar M, Ursic-Vrscaj M, Rakar S. Risk factors and prognostic factors in patients with double primary cancer: epithelial ovarian cancer and breast cancer. Eur J Gynaecol Oncol 2005;26:59-63.
6. Steinmann D, Bremer M, Rades D, Skawran B, Siebrands C, Karstens JH, Dörk T. Mutations of the BRCA1 and BRCA2 genes in patients with bilateral breast cancer. Br J Cancer 2001;85:850-8.
7. Ready KJ, Vogel KJ, Atchley DP, Broglio KR, Solomon KK, Amos C, Lu KH, Hortobagyi GN, Arun B. Accuracy of the BRCAPRO model among women with bilateral breast cancer. Cancer 2009;115:725-30.
8. Fletcher O, Johnson N, Dos Santos SI, Kilpivaara O, Aittomäki K, Blomqvist C, Nevanlinna H, Wasielewski M, Meijers-Heijerboer H, Broeks A, Schmidt MK, Van't Veer LJ, Bremer M, Dörk T, Chekmariova EV, Sokolenko AP, Imyanitov EN, Hamann U, Rashid MU, Brauch H, Justenhoven C, Ashworth A, Peto J. Family history, genetic testing, and clinical risk prediction: pooled analysis of CHEK2 c.1100delC in 1,828 bilateral breast cancers and 7,030 controls. Cancer Epidemiol Biomarkers Prev 2009;18:230-4.
9. Johnson N, Fletcher O, Naceur-Lombardelli C,dos Santos SI, Ashworth A, Peto J. Interaction between CHEK2*c.1100delC and other low-penetrance breast-cancer susceptibility genes: a familial study. Lancet. 2005;4:366.
10. Broeks A, de Witte L, Nooijen A, Huseinovic A, Klijn JG, van Leeuwen FE, Russell NS, van't Veer LJ. Excess risk for contralateral breast cancer in CHEK2*c.1100delC germline mutation carriers. Breast Cancer Res Treat 2004;83:91-3.
11. Evans DGR, Eccles DM, Rahman N, Young K, Bulman M, Amir E, Shenton A, Howell A, Lalloo F. A new scoring system for the chances of identifying a BRCA1/2 mutation, outperforms existing models including BRCAPRO. J Med Genet 2004;41:474-80.
12. Parmigiani G, Berry DA, Aquilar O. Determining carrier probabilities for breast cancer susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 1998;62:145-8.
13. Frank TS, Deffenbaugh AM, Reid JE, Hulick M, Ward BE, Lingenfelter B, Gumpper KL, Scholl T, Tavtigian SV, Pruss DR, Critchfield GC. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol 2002;20:1480-90.
14. McIntosh A, Shaw C, Evans G, Turnbull N, Bahar N, Barclay M, Easton D, Emery J, Gray J, Halpin J, Hopwood P, McKay J, Sheppard C, Sibbering M, Watson W, Wailoo A, Hutchinson A. Clinical guidelines and evidence review for the classification and care of women at risk of familial breast cancer. London: National Collaborating Center for Primary Care/University of Sheffield, 2004 updated 2006. NICE guideline CG041. http://www.nice.org.uk.
15. Antoniou AC, Cunningham AP, Peto J, Evans DG, Lalloo F, Narod SA, Risch HA, Eyfjord JE, Hopper JL, Southey MC, Olsson H, Johannsson O, Borg A, Passini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tryggvadottir L, Syrjakoski K, Kallioniemi OP, Eerola H, Nevanlinna H, Pharoah PD, Easton DF. The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer 2008;45:425-31.
16. Smith A, Moran A, Boyd MC, Bulman M, Shenton A, Smith L, Iddenden I, Woodward E, Lalloo F, Rahman N, Maher ER, Evans DGR. The trouble with phenocopies: are those testing negative for a family BRCA1/2 mutation really at population risk? J Med Genet 2007;44:10-15.
17. Gershoni-Baruch R, Dagan E, Fried G, Kepten I, Robinson E. BRCA1 and BRCA2 founder mutations in patients with bilateral breast cancer. Eur J Hum Genet 1999;7:833-6.
18. Bergthorsson JT, Ejlertsen B, Olsen JH, Borg A, Nielsen KV, Barkardottir RB, Klausen S, Mouridsen HT, Winther K, Fenger K, Niebuhr A, Harboe TL, Niebuhr E. BRCA1 and BRCA2 mutation status and cancer family history of Danish women affected with multifocal or bilateral breast cancer at a young age. J Med Genet 2001;38:361-8.
19. Evans DG, Lalloo F, Cramer A, Jones E, Knox F, Amir E, Howell A. Addition of pathology and biomarker information significantly improves the performance of the Manchester scoring system for BRCA1 and BRCA2 testing. J Med Genet 2009;46:811-817.
20. Johnson N, Fletcher O, Naceur-Lombardelli C,dos Santos SI, Ashworth A, Peto J. Interaction between CHEK2*c.1100delC and other low-penetrance breast-cancer susceptibility genes: a familial study. Lancet 2005;366:1554-7.
21. Kilpivaara O, Bartkova J, Eerola H, Syrjäkoski K, Vahteristo P, Lukas J, Blomqvist C, Holli K, Heikkilä P, Sauter G, Kallioniemi OP, Bartek J, Nevanlinna H. Correlation of CHEK2 protein expression and c.c.1100delC mutation status with tumor characteristics among unselected breast cancer patients. Int J Cancer 2005;113:575-80.
22. Naseem H, Boylan J, Speake D, Leask K, Shenton A, Lalloo F, Hill J, Trump D, Evans DGR. Inherited association of breast and colorectal cancer: limited role of CHEK2 compared to high-penetrance genes. Clin Genet 2006;70:388-95.